IP Library Granted Patent US 7,368,435
Granted Patent B2
US 7,368,435 · App. 11/221,654 · Granted May 6, 2008

Topical endoparasiticide and ectoparasiticide formulations

Assignee: Summit Vetpharm, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,368,435
App. No.
11/221,654
Granted
May 6, 2008
Kind
B2
Abstract

A topical formulation having significant parasiticidal activity effective against endoparasites and/or ectoparasites such as heartworms, mites, fleas, ticks, flies is provided, which can be safe to use and avoids the many common deleterious side effects of conventional topical formulations. The topical formulations comprise a combination of a macrocyclic lactone, a neo-nicotinoid and optionally, an insect growth regulator. The topical formulation can be packaged together or packaged so that the macrocyclic lactone and the neo-nicotinoid are stored separately prior to administering the topical insecticide formulation to the animal.

Claims (10)

1. A topical formulation comprising a first active ingredient comprising approximately 0.2 to 1.75 mg ivermectin per ml of total volume of formulation and a second active ingredient comprising 50 to 150 mg dinotefuran per ml of total volume of formulation, wherein the formulation further comprises (I) permethrin or phenothrin and (ii) an insect growth regulator comprising pyriproxyfen or methoprene, and wherein the first active ingredient and the second active ingredient are packaged with said permethrin or phenothrin, but isolated from interacting with said permethrin or phenothrin.

2. The topical formulation of claim 1 , wherein the active ingredients are isolated via the use of granulation, encapsulation, micelles, or encapsulated microbeads.

3. The topical formulation of claim 1 , wherein the formulation is not irritating to cats and dogs and is effective to kill endoparasites and ectoparasites with applications of less than 10 ml.

4. A method for treating endoparasitic or ectoparasitic infestation in an animal, the method comprising applying the topical formulation of claim 1 to the animal.

5. The method of claim 4 wherein the animal is a cat or a dog.

6. A topical formulation comprising a first active ingredient comprising approximately 0.2 to 1.75 mg ivermectin per ml of total volume of formulation and a second active ingredient comprising 50 to 150 mg dinotefuran per ml of total volume of formulation, wherein the formulation further comprises (i) permethrin or phenothrin and (ii) an insect growth regulator comprising pyriproxyfen or methoprene, wherein the ivermectin and dinotefuran are packaged in a first container, permethrin or phenothrin is packaged in a second container, and the insect growth regulator is packaged in either the first container or the second container, the first container. packaged in a manner in which it is separated from the second container, in order to prevent interaction with the second container prior to administrating the topical formulation.

7. The topical formulation of claim 6 , wherein the first and second containers are packaged together but separated by at least one barrier to prevent the interaction of the first container with the second container.

8. The topical formulation of claim 6 , wherein the formulation is not irritating to cats and dogs and is effective to kill endoparasites and ectoparasites with applications of less than 10 ml.

9. A method for treating endoparasitic or ectoparasitic infestation in an animal, the method comprising applying the topical formulation of claim 6 to the animal.

10. The method of claim 4 , wherein the animal is a cat or dog.

Assignments (4)
MERGER AND CHANGE OF NAME Recorded Oct 3, 2014
From: SUMMIT VETPHARM, LLC; CEVA ANIMAL HEALTH, INC.
To: CEVA ANIMAL HEALTH LLC
Reel/Frame 033884/0454 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2007
From: HARTZ MOUNTAIN CORPORATION, THE
To: SUMMIT VETPHARM, LLC
Reel/Frame 018731/0614 →
RE-RECORD TO CORRECT THE NAME OF THE FIRST ASSIGNOR, PREVIOUSLY RECORDED ON REEL 017528 FRAME 0432. Recorded May 11, 2006
From: COTTRELL, IAN WILLIAM; AHN, ALBERT; FISHER, RICHARD
To: HARTZ MOUNTAIN CORPORATION, THE
Reel/Frame 017613/0138 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2006
From: COTTROLL, IAN W.; AHN, ALBERT; FISHER, RICHARD
To: HARTZ MOUNTAIN CORPORATION, THE
Reel/Frame 017528/0432 →
Continuity (7)
Continuation In Part 1118134400 · Jul 14, 2005
Continuation In Part 1091054200 · Aug 3, 2004
Continuation In Part 1024255100 · Sep 12, 2002
Provisional Application 6060790000 · Sep 8, 2004
Provisional Application 6049397600 · Aug 8, 2003
Provisional Application 6055456300 · Mar 19, 2004
Related Publication 20060062817A1 · Mar 23, 2006